|
SD BIOSENSOR is a South Korean in vitro diagnostics (IVD) company that develops and manufactures medical devices and reagents for infectious disease and chronic disease testing. The company operates across four main technology platforms: rapid diagnostics, fluorescence immunoassay, enzyme immunoassay, and molecular diagnostics. Its product portfolio includes the STANDARD Q rapid test kits, the STANDARD F fluorescence immunoassay analyzers, the STANDARD E ELISA and IGRA systems, and the STANDARD M and STANDARD M10 molecular diagnostic platforms. The company also offers clinical chemistry solutions via the STANDARD C brand, which focuses on HbA1c testing, and blood glucose monitoring systems under the SD GlucoNavii brand. SD BIOSENSOR serves hospitals, clinical laboratories, and public health institutions globally, with a significant presence in international public procurement markets such as those managed by the Global Fund and UNICEF. The company holds certifications from the World Health Organization, the European Union, and the US Food and Drug Administration. It maintains a global distribution network through exclusive dealers and direct sales subsidiaries in regions including India, Indonesia, Brazil, and the United States. The company's business model relies on the sale of diagnostic instruments and the recurring revenue from associated reagents and consumables. Summarised from the company's own disclosures, fiscal year ended Mar 2026 |
Industry Diagnostics & Research | Homepage sdbiosensor.co.kr |
| Sector Healthcare | IR page sdbiosensor.co.kr | |
|
Tags
in vitro diagnostics, rapid diagnostics, molecular diagnostics, immunoassay, clinical chemistry, blood glucose monitoring, infectious disease testing, chronic disease management, point-of-care testing, medical devices, STANDARD Q, STANDARD F, STANDARD E, STANDARD M, STANDARD M10, STANDARD i, STANDARD C, SD GlucoNavii, TB-Feron, SD Biosensor Healthcare Pvt Ltd., PT. SD Biosensor Healthcare, ECO Diagnostica Ltda., Bestbion dx GmbH, Mirero Corp., Meridian Bioscience
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | ₩ 994.081B |
| Market cap (USD) | $ 731.626M |
| P/E | -1.34 |
| PEG | — |
| P/BV | 0.41 |
| P/S | 1.35 |
| P/OCF | 17.52 |
| P/FCF | 89.32 |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | -19.5% |
| ROI | -22.0% |
| ROIC | -2.6% |
| Profit margin | -72.1% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | No |
| Revenue up 3y | No |
| Revenue up 5y | — |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | No |
| Margin expanding | No |
| Buying back stock | — |
| Diluting (TTM) | — |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | — |
| Quality score | -57.1% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Balance sheet detail | |||||
| Trade receivables (KRW) | 208B | 108B | 141B | 136B | 138B |
| ↳ YoY growth | -48.0% | +30.1% | -2.9% | +1.2% | |
| Borrowings, current (KRW) | 0.00 | 450M | 129B | — | 1.57B |
| Borrowings, non-current (KRW) | 275M | 147M | 282B | 338B | 347B |
| Lease liabilities (KRW) | 24.7B | 24.2B | 12.7B | 20.2B | 17B |
| Cash and deposits (KRW) | 882B | 1.87T | 482B | 177B | 367B |
| Intangible assets (KRW) | 38B | 67.4B | 1.94T | 2.09T | 1.26T |
| Net debt (borrowings + leases - cash) (KRW) | -857B | -1.85T | -58B | 180B | -2.96B |
| Cash flow detail | |||||
| Operating cash flow (KRW) | 1.23T | 889B | -242B | 157B | 358B |
| Purchases of property, plant and equipment (KRW) | -97.3B | -297B | -143B | -78.8B | -57.1B |
| Purchases of intangible assets (KRW) | -1.98B | -3.34B | -2.12B | -2.12B | -404M |
| Dividends paid (cash effect) (KRW) | -49.8B | -199B | -29.5B | -38.1M | -24.2B |
| Share buybacks (cash effect) (KRW) | -99.6B | 0.00 | 0.00 | -18.4B | -11.6B |
| Interest paid (cash effect) (KRW) | -498M | -985M | -191B | -31.9B | -25.7B |
| Income taxes paid (cash effect) (KRW) | -133B | -537B | -199B | 84.5B | 338B |
| Free cash flow (OCF - PPE - intangibles) (KRW) | 1.14T | 589B | -387B | 75.6B | 300B |
| Income detail | |||||
| Total comprehensive income (KRW) | 1.09T | 912B | -396B | 118B | -561B |
| Comprehensive income to owners (KRW) | 1.09T | 915B | -396B | 117B | -559B |
| Reported | Aug 22, 2025 | Aug 22, 2025 | Aug 22, 2025 | Aug 22, 2025 | May 14, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpDisclosures filed with DART (material events and exchange disclosures), newest first, headlines as filed in Korean. The link opens the filing on DART. Press releases from the company's own website, newest first.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding SD BIOSENSOR
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| AVEE | 0.01% | 2,479 | $ 13.804K | Nov 16, 2026 |
| DFEM | 0.00% | 54,883 | $ 292.06K | Nov 12, 2026 |
| DEXC | 0.00% | 808 | $ 4,299.78 | Nov 12, 2026 |
| AVEM | 0.00% | 41,043 | $ 228.545K | Nov 16, 2026 |
| AVES | 0.00% | 1,247 | $ 6,943.82 | Nov 16, 2026 |
| AVSE | 0.00% | 1,269 | $ 7,066.32 | Nov 16, 2026 |
| AVXC | 0.00% | 70 | $ 389.79 | Nov 16, 2026 |






































